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The effects of antiepileptic drugs (AEDs) on bone mineral density
(BMD) are well addressed, but data on children, especially con-
cerning new antiepileptic medications, are scarce. This study
aimed to reveal the impact of these drugs on the BMD of am-
bulatory patients with epilepsy. Methods: BMD and detailed
clinical information were obtained on 108 patients and 38 con-
trols using dual-energy x-ray absorptiometry. The patients were
categorized into 2 groups: enzyme-inducing AEDs (EIAEDs) and
non-EIAEDs. Also, the patients were classified as being in either
a monotherapy or a polytherapy group. All patients completed
a 63-item questionnaire. In this study, the raw value of BMD,
T score, and z score of the spine, neck of femur, total hip, and
forearm were analyzed. Results: Patients receiving AEDs showed
diminished lumbar BMD, compared with controls (P , 0.05),
regardless of the type of AED (EIAEDs or non-EIAEDs). In ad-
dition, there was a significant decrease in femoral neck BMD in
patients receiving EIAEDs (0.922 6 0.161, P , 0.05) but not in
those treated with non-EIAEDs. Patients undergoing carbama-
zepine monotherapy (33 patients) showed diminished lumbar
and femoral neck BMD, whereas those receiving valproate (22
patients) or undergoing polytherapy showed a BMD similar to
that of controls in all studied regions of interest. There was no
notable change in BMD in the Ward triangle, trochanter, or total
hip in either the EIAED or the non-EIAED group. Conclusion: AED
therapy, especially in patients on new-generation medication, is
associated with low bone density. It is hoped that the presented
data stressing several clinical and diagnostic points will stimu-
late a high index of suspicion to facilitate early diagnosis and
preventive care.
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Drug-induced osteoporosis is common in the treatment
of chronic debilitating diseases such as epilepsy (1). Anti-
epileptic drugs (AEDs) are associated with decreased bone
mineral density (BMD) and increased fracture risk (2). In-
creased metabolism of 25-hydroxyvitamin D to inactive
metabolites after cytochrome p450 induction is thought to
be the main mechanism of bone loss by enzyme-inducing
AEDs (EIAEDs: phenobarbital, carbamazepine, oxcarba-
mazepin, phenytoin) (3–6). On the other hand, pregnane X
receptor, a nuclear receptor activated by xenobiotic com-
pounds, including phenytoin phenobarbital and even val-
proic acid, promotes the expression of vitamin D–responsive
genes, including those responsible for vitamin D metabo-
lism (2,7). Bone resorption due to secondary hyperparathy-
roidism is also demonstrated for phenytoin but not for
carbamazepine, valproate, or lamotrigine (2,8). In addition,
some studies have not found a significant association be-
tween vitamin D, parathyroid hormone, and AEDs (6,9).
Inhibition of intestinal absorption of calcium, activation
of vitamin D, and an increase in osteoblasts are also reported
to play a role in AED-induced bone loss, even non-EIAEDs
(2,10). Furthermore, the fact that bone loss does not appear
simultaneously in all regions may interfere with the inter-
pretation of BMD data.
In this study, we aimed to investigate the possible effect
of antiepileptic treatment on BMD in different regions of
interest (ROIs).
MATERIALS AND METHODS
Participants and Study Design
Patients receiving different AEDs were studied for BMD. Also,
some patients who were taking new-generation antiepileptic medi-
cation such as lamotrigine, topiramate, clonazepam, and ethosux-
imide were included in this study. Overall, the study comprised
108 patients and 38 control subjects. The patients were categorized
according to their treatment protocol (monotherapy or polyther-
apy) and type of drug (enzyme-inducer [phenytoin, phenobarbital,
carbamazepine] or non–enzyme inducer [valproate, ethosuximide,
lamotrigine, clonazepam]). Patients with hyperparathyroidism, re-
nal failure, or menopause and those undergoing hormone replace-
ment therapy or corticosteroid/anticoagulant therapy were excluded.
Received Apr. 10, 2013; revision accepted Jun. 4, 2013.
For correspondence or reprints contact: Majid Assadi, Persian Gulf Nuclear
Medicine Research Center, Bushehr University of Medical Sciences, Bushehr
3631, Iran.
E-mail: assadipoya@yahoo.com, asadi@bpums.ac.ir
Published online Jul. 25, 2013.
COPYRIGHT ª 2013 by the Society of Nuclear Medicine and Molecular
Imaging, Inc.
208 JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY • Vol. 41 • No. 3 • September 2013
by Yale University Medical Library on July 10, 2015. For personal use only. tech.snmjournals.org Downloaded from 
All participants completed a detailed 63-item questionnaire that
gathered demographic and behavioral data and asked about a med-
ical history of conditions that could affect bone mass and me-
tabolism. The body mass index is described as the individual’s body
mass divided by the square of height (kg/m2).
The study complied with the Declaration of Helsinki and was
confirmed by the institutional ethics committee of Bushehr Univer-
sity of Medical Sciences.
BMD
BMD was determined for the spine (L2–L4), greater trochanter,
Ward triangle, and femoral neck using dual-energy x-ray absorp-
tiometry (Osteocore II [Medilink] discrepancies). The Ward tri-
angle characterizes the region in the femoral neck with the fewest
trabeculae and thus is the area of least BMD. The location of the
Ward triangle is patient-specific, and its area is small in compar-
ison to the size of the femur.
World Health Organization criteria were used to determine the
ROI T score (the bone mineral density at the site, compared with
the young reference mean). Patients were considered to have
normal bone density (T score . 21 SD), osteopenia (21 SD , T
score , 22.5 SDs), or osteoporosis (T score , 22.5 SDs). The
nuclear medicine specialist interpreting the results was not aware
of the type of protocol or antiepileptic therapy.
Statistical Analysis
One-way ANOVAwas used to compare BMD values in patients
receiving monotherapy or polytherapy and enzyme-inducer or non–
enzyme-inducer agents. Linear regression analysis was performed
to detect the possible influence of different variables on BMD. SPSS
software, version 18 (SPSS, Inc.), was used for statistical analysis;
the data are presented as mean 6 SEM, and a P value of less than
0.05 was considered significant.
RESULTS
The data regarding the effects of drug type and protocol
on BMD are presented in Tables 1 and 2.
The study included 108 patients (51 men and 62 women;
age, 21.8 6 10.31 y) receiving different AEDs for 43.18 6
30.78 mo. We also included 38 healthy controls (8 men and
30 women; age, 30 6 6.13 y).
Patients receiving AEDs showed a diminished lumbar
BMD, compared with controls (P , 0.05), but there was no
significant difference between the groups regarding the type
of AED (inducer or noninducer). In addition, there was
a significant decrease in femoral neck BMD in patients
receiving EIAEDs (0.922 6 0.161, P , 0.05) but not in
those treated with non-EIAEDs.
Individual comparison of the drugs showed that patients
receiving carbamazepine (33 patients) had a diminished
lumbar BMD (0.848 6 0.213 vs. 1.029 6 0.131, P , 0.01)
and femoral neck BMD (0.877 6 0.174 vs. 1.004 6 0.102,
P, 0.01), compared with controls, whereas those receiving
valproate (22 patients) showed a BMD similar to that of
controls in all studied ROIs. In addition, there was no sig-
nificant difference between patients undergoing polyther-
apy and the control group. We could not find a significant
difference between the BMD values of patients and controls
in the greater trochanter, Ward triangle, or total hip, regard-
less of type of treatment (EIAEDs or non-EIAEDs) or pro-
tocol (monotherapy or polytherapy).
Linear regression analysis revealed that body mass index
was positively associated with increased BMD in the lum-
bar spine (b 5 0.42, P , 0.001), femoral neck (b 5 0.44,
P, 0.001), greater trochanter (b5 0.46, P, 0.001), Ward
triangle (b 5 0.21, P , 0.05), and total hip (b 5 0.37, P ,
0.001).
We did not find a notable difference in BMD regarding
sun exposure. On the other hand, smoking (7 patients) was
remarkably associated with a low BMD in the spine (0.73 6
0.13 vs. 0.91 6 0.20, P , 0.05), femoral neck (0.79 6 0.15
vs. 0.93 6 0.16, P , 0.05), greater trochanter (0.57 6 0.08
vs. 0.91 6 0.20, P , 0.05), and total hip (0.66 6 0.15 vs.
0.807 6 0.19, P , 0.05)
TABLE 1
The Effects of Drug Type on BMD
Region Group n Mean SD 95% CI
Lumbar spine Control 38 1.029 0.131 0.986–1.072
EIAEDs 72 0.906* 0.203 0.858–0.954
Non-EIAEDs 36 0.905* 0.215 0.832–0.977
Ward triangle Control 38 0.873 0.254 0.79–0.957
EIAEDs 72 0.776 0.344 0.695–0.856
Non-EIAEDs 36 0.772 0.375 0.645–0.899
Greater trochanter Control 38 0.729 0.119 0.690–0.769
EIAEDs 72 0.682 0.134 0.651–0.714
Non-EIAEDs 36 0.722 0.143 0.674–0.771
Femoral neck Control 38 1.004 0.102 0.971–1.038
EIAEDs 72 0.922* 0.161 0.884–0.96
Non-EIAEDs 36 0.946 0.164 0.890–1.001
Total hip Control 38 0.869 0.141 0.822–0.915
EIAEDs 72 0.793 0.184 0.75–0.837
Non-EIAEDs 36 0.813 0.203 0.745–0.882
*P , 0.05, compared with control.
CI 5 confidence interval.
ANTIEPILEPTIC TREATMENT AND BMD • Salimipour et al. 209
by Yale University Medical Library on July 10, 2015. For personal use only. tech.snmjournals.org Downloaded from 
DISCUSSION
We observed a significant decrease in lumbar BMD among
patients receiving AEDs regardless of the inducer or nonin-
ducer drug. Although EIAEDs enhance vitamin D metab-
olism to inactive metabolites (3–6), non-EIAEDs may also
contribute to bone loss by interfering with pregnane X re-
ceptor, intestinal absorption of calcium, activation of vita-
min D, osteoblast cell growth, or homocysteine accumulation
(2,10,11). Boluk et al. reported that long-term (.1 y) mo-
notherapy of epileptic adults with valproate reduces BMD.
They have also demonstrated an increase in the serum lev-
els of parathyroid hormone, phosphorus, and alkaline phos-
phatase (12).
In addition, a decline in femoral neck BMD was seen in
patients treated with EIAEDs but not in those receiving
non-EIAEDs. Stephen et al. reported a reduction in femoral
neck BMD in 78 epileptic patients receiving EIAEDs (car-
bamazepine and phenytoin) or non-EIAEDs (mainly val-
proate), including 47 postmenopausal women (13). Moreover,
Pack et al. described a 2.6% decline of BMD in the femoral
neck but not in the lumbar spine or total hip of 93 premeno-
pausal women receiving AEDs for 1 y (8).
There was no notable change in BMD in the Ward
triangle, trochanter, or total hip in either the EIAED group
or the non-EIAED group. These observations suggest that
one ROI may show bone resorption whereas the other ROIs
represent normal BMD. Moreover, compiling the data on
the femoral neck, greater trochanter, and Ward triangle into
total-hip BMD may mask the alterations of BMD in these
regions. In this regard, Selby et al. reported that the error
associated with total-hip BMD derived from the hip
subregions (59%) is too high to allow clinically meaningful
conclusions (14). Total-hip calibration formulas can also
influence BMD differences between the different scanners
in hip subregions. Therefore, subregion calibration formulas
should be applied for calibration of absolute changes (15).
Patients undergoing carbamazepine monotherapy (33 pa-
tients) showed diminished lumbar and femoral neck BMD,
whereas those receiving valproate (22 patients) or under-
going polytherapy showed BMD similar to that of controls
in all studied ROIs. Chou et al. have also demonstrated
diminished bone density in children receiving carbamaze-
pine monotherapy, compared with those undergoing valproate
monotherapy (16).
We also studied patients receiving lamotrigine, topiramate,
clonazepam, and ethosuximide. However, they were also
treated with one of the conventional drugs. Therefore, we
could not distinguish the main effect of these agents on bone
density. In this regard, a retrospective cohort study has found
that newer non-EIAEDs (gabapentin, lamotrigine, and
topiramate) are less likely to be associated with osteopo-
rosis at the lumbar spine, femoral neck, and total hip (17).
Treatment with more than one AED and with EIAEDs is
considered to be more commonly associated with a risk of
fracture in postmenopausal women (18). In contrast, combi-
nation therapy did not result in reduced BMD in any of the
studied ROIs in our study. This inconsistency may result from
the difference in population or the type of drug combination.
In contrast to Andress et al., who reported age and du-
ration of treatment as critical risk factors for low BMD in
men receiving AEDs (19), we observed that neither age nor
duration of AED treatment significantly influenced BMD.
TABLE 2
The Effects of Monotherapy or Polytherapy on BMD
Region Therapy n Mean SD 95% CI
Lumbar spine Polytherapy 52 0.933 0.188 0.881–0.985
Carbamazepine monotherapy 33 0.848* 0.213 0.772–0.924
Valproate monotherapy 22 0.917 0.231 0.814–1.019
Control 38 1.0289 0.131 0.986–1.072
Ward triangle Polytherapy 52 0.792 0.307 0.706–0.877
Carbamazepine monotherapy 33 0.744 0.394 0.604–0.884
Valproate monotherapy 22 0.781 0.407 0.601–0.962
Control 38 0.873 0.254 0.79–0.957
Greater trochanter Polytherapy 52 0.708 0.140 0.669–0.747
Carbamazepine monotherapy 33 0.656 0.134 0.608–0.703
Valproate monotherapy 22 0.731 0.133 0.671–0.79
Control 38 0.729 0.119 0.69–0.769
Femoral neck Polytherapy 52 0.938 0.1507 0.896–0.98
Carbamazepine monotherapy 33 0.887** 0.174 0.825–0.949
Valproate monotherapy 22 0.974 0.163 0.901–1.046
Control 38 1.004 0.102 0.971–1.038
Total hip Polytherapy 52 0.813 0.161 0.768–0.857
Carbamazepine monotherapy 33 0.762 0.213 0.686–0.838
Valproate monotherapy 22 0.828 0.217 0.732–0.925
Control 38 0.869 0.141 0.823–0.915
*P , 0.01 compared with control.
CI 5 confidence interval.
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This controversy may result from the fact that we included
both male and female patients. Moreover, most of our
patients underwent combination therapy.
Smoking was notably associated with low bone density
in the spine, femoral neck, greater trochanter, and total
hip. This finding suggests that alteration of lifestyle may
help improve bone health in patients receiving AEDs.
However, Lyngstad-Brechan reported a diminished mean
BMD at the proximal forearm and femoral neck of
postmenopausal women receiving anticonvulsants, com-
pared with an age- and lifestyle-matched (smoking habits,
physical activity) control group (20). Likewise, an accel-
eration of bone loss with anticonvulsants has been found
even after adjustment for age, smoking, body mass index,
health status, and calcium and vitamin D intake (hip
BMD loss, 1.16% in 1 y vs. 0.70% in controls) (21). These
observations suggest that prevention of bone loss in epileptic
patients requires more serious clinical management (22).
CONCLUSION
Antiepileptic treatment, especially carbamazepine mono-
therapy, is associated with decreased BMD. This decrease of
BMD may not appear simultaneously in all regions on dual-
energy x-ray absorptiometry scans, suggesting that scanning
for BMD be repeated in several ROIs in clinical evaluations.
DISCLOSURE
This study is the thesis of Dr. Sara Kazerooni and was
carried out with the sponsorship of Bushehr University of
Medical Sciences (grant 1249). No other potential conflict
of interest relevant to this article was reported.
ACKNOWLEDGMENTS
We thank our colleagues at our institutes for technical
help and data acquisition.
REFERENCES
1. Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: mechanisms and
clinical implications. Am J Med. 2010;123:877–884.
2. Lee RH, Lyles KW, Colon-Emeric C. A review of the effect of anticonvulsant
medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother.
2010;8:34–46.
3. Dent CE, Richens A, Rowe DJ, Stamp TC. Osteomalacia with long-term anti-
convulsant therapy in epilepsy. BMJ. 1970;4:69–72.
4. Hahn TJ, Hendin BA, Scharp CR, Haddad JG Jr. Effect of chronic anticonvulsant
therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med. 1972;
287:900–904.
5. Hahn TJ, Birge SJ, Scharp CR, Avioli LV. Phenobarbital-induced alterations in
vitamin D metabolism. J Clin Invest. 1972;51:741–748.
6. Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover
in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia. 2006;47:
510–515.
7. Cerveny L, Svecova L, Anzenbacherova E, et al. Valproic acid induces CYP3A4
and MDR1 gene expression by activation of constitutive androstane receptor and
pregnane X receptor pathways. Drug Metab Dispos. 2007;35:1032–1041.
8. Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E. Bone health in young
women with epilepsy after one year of antiepileptic drug monotherapy. Neurol-
ogy. 2008;70:1586–1593.
9. Filardi S, Guerreiro CA, Magna LA, Marques Neto JF. Bone mineral density,
vitamin D and anticonvulsant therapy. Arq Neuropsiquiatr. 2000;58:616–620.
10. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover
with valproate therapy in adults with epilepsy. Neurology. 2001;57:445–449.
11. Elliott JO, Jacobson MP, Haneef Z. Homocysteine and bone loss in epilepsy.
Seizure. 2007;16:22–34.
12. Boluk A, Guzelipek M, Savli H, Temel I, Ozisik HI, Kaygusuz A. The effect of
valproate on bone mineral density in adult epileptic patients. Pharmacol Res.
2004;50:93–97.
13. Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic
drugs: a case-controlled study. Seizure. 1999;8:339–342.
14. Selby PL, McCloskey EV, Robinson J, et al. Is a calculated total hip BMD of
clinical use? Osteoporosis International. 2000;11:368–371.
15. Lu Y, Fuerst T, Hui S, Genant HK. Standardization of bone mineral density at
femoral neck, trochanter and Ward’s triangle. Osteoporosis International. 2001;12:
438–444.
16. Chou IJ, Lin KL, Wang HS, Wang CJ. Evaluation of bone mineral density in
children receiving carbamazepine or valproate monotherapy. Acta Paediatr Taiwan.
2007;48:317–322.
17. Lee RH, Lyles KW, Sloane R, Colon-Emeric C. The association of newer anti-
convulsant medications and bone mineral density. Endocr Pract. September 14,
2012 [Epub ahead of print].
18. Carbone LD, Johnson KC, Robbins J, et al. Antiepileptic drug use, falls, frac-
tures, and BMD in postmenopausal women: findings from the women’s health
initiative (WHI). J Bone Miner Res. 2010;25:873–881.
19. Andress DL, Ozuna J, Tirschwell D, et al. Antiepileptic drug-induced bone loss
in young male patients who have seizures. Arch Neurol. 2002;59:781–786.
20. Lyngstad-Brechan MA, Tauboll E, Nakken KO, et al. Reduced bone mass and
increased bone turnover in postmenopausal women with epilepsy using antiep-
ileptic drug monotherapy. Scand J Clin Lab Invest. 2008;68:759–766.
21. Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL.
Antiepileptic drug use increases rates of bone loss in older women: a prospective
study. Neurology. 2004;62:2051–2057.
22. Elliott JO. Possible methods for the prevention of bone loss in persons with
epilepsy. Expert Rev Neurother. 2009;9:797–812.
ANTIEPILEPTIC TREATMENT AND BMD • Salimipour et al. 211
by Yale University Medical Library on July 10, 2015. For personal use only. tech.snmjournals.org Downloaded from 
Doi: 10.2967/jnmt.113.124685
Published online: July 25, 2013.
2013;41:208-211.J. Nucl. Med. Technol. 
  
Majid Assadi
Hooman Salimipour, Sara Kazerooni, Mohammad Seyedabadi, Iraj Nabipour, Reza Nemati, Darioush Iranpour and
  
Region of Interest
Antiepileptic Treatment Is Associated with Bone Loss: Difference in Drug Type and
 http://tech.snmjournals.org/content/41/3/208
This article and updated information are available at: 
  
 http://tech.snmjournals.org/site/subscriptions/online.xhtml
Information about subscriptions to JNMT can be found at: 
  
 http://tech.snmjournals.org/site/misc/permission.xhtml
Information about reproducing figures, tables, or other portions of this article can be found online at: 
(Print ISSN: 0091-4916, Online ISSN: 1535-5675)
1850 Samuel Morse Drive, Reston, VA 20190.
SNMMI | Society of Nuclear Medicine and Molecular Imaging is published quarterly.Journal of Nuclear Medicine Technology
© Copyright 2013 SNMMI; all rights reserved.
by Yale University Medical Library on July 10, 2015. For personal use only. tech.snmjournals.org Downloaded from 
